{Reference Type}: Journal Article
{Title}: Use of Bladder Epicheck® in the follow-up of high-risk non-muscle-invasive Bladder cancer: A systematic literature review.
{Author}: Caño Velasco J;Artero Fullana S;Polanco Pujol L;Lafuente Puentedura A;Subiela JD;Aragón Chamizo J;Moralejo Gárate M;Hernández Fernández C;
{Journal}: Actas Urol Esp (Engl Ed)
{Volume}: 0
{Issue}: 0
{Year}: 2024 May 10
暂无{DOI}: 10.1016/j.acuroe.2024.05.004
{Abstract}: <B>BACKGROUND: </B>In recent years, different urinary markers such as the Bladder Epicheck® have been developed in an attempt to reduce the number of cystoscopies in the follow-up of non-muscle invasive bladder cancer (NMIBC).<BR><B>OBJECTIVE: </B>To provide a systematic review of Bladder Epicheck® and its current clinical utility in the follow-up and detection of recurrence of NMIBC.<BR><B>METHODS: </B>Systematic review based on a literature search of PubMed, Web of Science and Scopus databases until October 2023, according to PRISMA and Quadas-2 criteria. Sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) of the marker were calculated. Diagnostic performance was evaluated by the area under the curve (AUC).<BR><B>RESULTS: </B>Fifteen studies were analyzed (n = 3761) including 86.7% prospective studies. Of the patient series, 53.2% had received previous intravesical instillations. The mean Se of the biomarker in the detection of recurrence varied according to tumor grade (87.9%-high grade/HG vs. 44.9%-low grade/LG, respectively). Their weighted mean Se and Sp were 71.6% and 84.5%, respectively. The mean recurrence rate was 29.1%. The weighted mean PPV and NPV were 56.4% and 92.8% (97.7% non-LG), respectively. The mean AUC was 85.63%.<BR><B>CONCLUSIONS: </B>Bladder Epicheck® is a useful urinary marker in the follow-up of NMIBC, with significantly high Se and NPV in the detection of recurrences, especially in cases of HG disease. Its use can reduce the number of cystoscopies required in the follow-up of NMIBC, improving the quality of life of patients and potentially increasing health economic savings.